Please ensure Javascript is enabled for purposes of website accessibility

Shares of Mesoblast Tumbled Over 20% Today After Doubling Last Week

By Maxx Chatsko – Updated Apr 27, 2020 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian stem-cell therapy developer presented promising data for COVID-19 patients days ago, but investors took some gains off the table today.

What happened

Shares of Mesoblast (MESO -0.32%) fell as much as 22.3% today as investors decided to lock in gains. The stem-cell stock erupted for a 139% gain on Friday after data from a small study suggested the company's cell therapy might significantly improve outcomes for COVID-19 patients placed on mechanical ventilators. 

The promising early stage results pushed the company's market cap to over $1.6 billion. Mesoblast had been valued at $450 million a few weeks earlier. Today's move suggests investors are taking the biopharma's inexperience and the preliminary nature of the study's data into account. 

As of 3:58 p.m. EDT on Monday, the small-cap stock had settled to a 21.5% loss.

A steadily ascending graph on a chalkboard that suddenly declines.

Image source: Getty Images.

So what

In March and April, Mesoblast conducted a small study at New York City's Mount Sinai Hospital to evaluate if its lead drug candidate, remestemcel-L, could treat acute respiratory distress syndrome (ARDS) in individuals with COVID-19. Doctors administered two doses of the experimental therapy within five days of patients being placed on a mechanical ventilator. The study was conducted using an emergency compassionate-use order and was not considered a clinical trial.

Of the 12 individuals in the study, 10 survived and nine had been removed from ventilators at a median time of 10 days. That represents a survival rate of 83% and indicates 75% of patients improved enough to come off ventilator support relatively quickly. 

All patients had received other experimental drugs, and the study was very small. But investors chose to focus on the remarkable outcome, especially when an observational study of 2,600 COVID-19 patients on ventilator support in New York City hospitals found that 88% died. 

Now what

Mesoblast intends to use the 12-patient study to influence the design of a larger clinical trial studying remestemcel-L in the same patient population, with participation from medical centers across North America. It's plausible that some types of stem cells could help to relieve ARDS in COVID-19 patients, but investors need to remain cautious until the results are replicated in larger populations. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mesoblast Limited Stock Quote
Mesoblast Limited
$2.72 (-0.32%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.